Skip to main content
Eyebrow
OUTBREAKS OBSERVE NO BORDERS

Headline
Novavax is uniquely qualified to address the enduring need for innovative vaccines

Text

Who is Novavax?

We are a late-stage biotechnology company that promotes improved global health through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases.

We have more than a decade of experience contending with some of the world’s most devastating diseases, including COVID-19, seasonal influenza, RSV, Ebola, MERS, and SARS. Hard-won lessons and significant advances illustrate that our proven technology has tremendous potential to make a substantial contribution to public health worldwide.

Our vaccine candidates are genetically engineered using three-dimensional nanostructures of recombinant proteins critical to disease pathogenesis.

We are also developing proprietary immune-stimulating saponin-based adjuvants at Novavax AB, our wholly owned Swedish subsidiary. Matrix-M™ has been shown to enhance immune responses and has been well tolerated in multiple clinical trials.

Dr. Nita Patel, Kelsey Jacobson, Dr. Rhonda Flores, and Dr. Sonia Maciejewski
Image Caption

Dr. Nita Patel, Kelsey Jacobson, Dr. Rhonda Flores, and Dr. Sonia Maciejewski are on the research team working on the genetic sequencing for vaccine candidate development.

Person with gloved hands inserting a syringe into a vial
Main Content

Our Team

Our team is composed of experts in drug development who understand science, technology, medicine, and their global context. Our deeply experienced team is unified in the quest to reduce the burden of infectious disease around the globe.

Secondary content

Meet the leaders who work relentlessly to address urgent global health needs.

Healthcare professional wearing personal protective equipment.
Eyebrow
ADDRESSING GLOBAL HEALTH CHALLENGES TOGETHER
Main Content

Our Partners and
Key Collaborators

Partners energize our mission and expand our reach

Novavax has several active partnerships across the globe. We seek and encourage meaningful partnerships and collaborations with leading biopharma organizations, research institutions, government agencies, and foundations.

Our partners and key collaborators

Our partners and key collaborators

Coalition for Epidemic Preparedness Innovations (CEPI) has committed to provide Novavax up to $388 million in funding for development and manufacturing of Novavax’ NVX-CoV2373 coronavirus vaccine candidate against SARS-CoV-2.

Learn About

The mission of CEPI is to stimulate and accelerate the development of vaccines against emerging infectious diseases and enable access to these vaccines for people during outbreaks.

Learn More
The real metrics of success for CEPI are whether it can develop the vaccines we need and whether CEPI can ensure that they’re going to be available to the individuals and populations that need them. CEPI is trying to have vaccines developed and tested faster than any previous effort, anywhere, ever. This is what CEPI was created to do.
Richard Hatchett
Chief Executive Officer
CEPI
Update
Novavax to receive up to $388 million in funding from CEPI for COVID-19 vaccine development and manufacturing

CEPI will invest up to $384 million of additional funding, on top of the $4 million it invested in March, to advance the clinical development of NVX-CoV2373, Novavax’ coronavirus vaccine candidate for SARS-CoV-2.

The additional funding from CEPI will also support the rapid scale-up of the NVX-CoV2373 vaccine antigen, as well as the Novavax proprietary Matrix-M™ adjuvant, which is expected to enhance immune responses by stimulating high levels of neutralizing antibodies. In addition, the CEPI funding will allow Novavax to dramatically increase its large-scale manufacturing capacity for both antigen and adjuvant in multiple locations.

The Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) is the Joint Service’s lead for development, acquisition, fielding, and life-cycle support of chemical, biological, radiological, and nuclear defense equipment and medical countermeasures.

Learn About

JPEO-CBRND Enabling Biotechnologies (EB) provides new and improved medical countermeasure responses during a crisis and against future threats.

Learn More
Our vision is a resilient Joint Force enabled to fight and win, unencumbered by a chemical, biological, radiological, or nuclear environment and championed by innovative and state-of-the-art solutions.
Update
Novavax awarded Department of Defense contract for COVID-19 vaccine

Novavax has been awarded a contract by the US Department of Defense (DoD) for the manufacturing of NVX-CoV2373, Novavax’ COVID-19 vaccine candidate. JPEO-CRBND-EB, through funding provided by the Defense Health Program, has agreed to fund up to $60 million to support Novavax in its production of several components of the vaccine that will be manufactured in the United States. The agreement includes a 2020 delivery of 10 million doses of NVX-CoV2373 for DoD that could be used in Phase 2/3 clinical trials or under an Emergency Use Authorization (EUA) if approved by the US FDA.

Novavax and Serum Institute of India (SII) announced a commercial license agreement for the use of Novavax’ proprietary Matrix-M™ vaccine adjuvant with SII’s malaria vaccine candidate.

Learn About

Serum Institute of India is the world’s largest vaccine manufacturer based on the number of doses produced and sold globally (more than 1.5 billion doses), which include the polio vaccine as well as the diphtheria, tetanus, pertussis, Hib, BCG, hepatitis B, measles, mumps, and rubella vaccines.

Learn More
This will be an important long-term partnership in advancing an innovative potential malaria vaccine. While we have much work to do, this marks a key step forward. Both in the Indian and international markets, Serum Institute of India aims to provide necessary vaccine coverage with ease of access and at affordable prices.
Adar C. Poonawalla
Chief Executive Officer
Serum Institute of India
Update
Novavax and Serum Institute of India have partnered to develop and commercialize a malaria vaccine candidate

Novavax and Serum Institute of India announced a commercial license agreement for the use of the Novavax proprietary Matrix-M vaccine adjuvant with Serum Institute of India’s malaria vaccine candidate. Serum Institute of India licensed the R21 malaria vaccine, which targets the most severe plasmodium falciparum–induced malaria disease, from the Jenner Institute at Oxford University in 2017. Matrix-M is a key component in the malaria vaccine candidate, currently in a Phase 2b clinical trial sponsored by the Jenner Institute with top-line data expected to be reported in the second quarter of 2020.

In 2009, Novavax formed CPL Biologicals Ltd., a joint venture with Cadila Pharmaceuticals Ltd., to develop a number of Novavax’ VLP vaccine candidates and certain Cadila therapeutic vaccine candidates for territories in India.

Learn About

Cadila Pharmaceuticals Ltd. is one of the largest privately held pharmaceutical companies in India. The mission of Cadila Pharmaceuticals is to discover, develop, and successfully market pharmaceutical products to prevent, diagnose, alleviate, and cure diseases.

Learn More
Cadila Pharmaceuticals is one of India’s most advanced and respected pharmaceutical companies. In Novavax, we believe that we have found the best combination of an advanced and proven technology platform for creating next generation vaccines.
Dr. Rajiv Modi
Managing Director
Cadila Pharmaceuticals Ltd.
Update
Novavax and Cadila Pharmaceuticals Ltd. formed a joint venture to expand vaccine development capabilities and global manufacturing capacity

In 2009, Novavax formed CPL Biologicals Ltd., a joint venture with Cadila Pharmaceuticals Ltd. to develop a number of Novavax’ VLP vaccine candidates and certain Cadila therapeutic vaccine candidates for territories in India.

Scientist, standing, wearing gloves and goggles, and using a computer workstation.
Main Content

Request for proposal
(RFP) overview

Novavax announces projects that are open for competitive bidding.

Novavax is developing NVX-CoV2373, a new vaccine for SARS-CoV-2, in partnership with the Coalition for Epidemic Preparedness Innovations (CEPI). To rapidly advance the program and deliver experimental vaccine doses as soon as possible, Novavax is requesting proposals for multiple projects.

For a list of open requests for proposal or if you would like instructions on how to participate in an RFP issued by Novavax, download our RFP Information Document.

Call-to-action buttons
Secondary content

For business development inquiries,
contact
 busdev@novavax.com